WA-ITRON
14.2.2024 14:46:26 CET | Business Wire | Press release
Itron, Inc. (NASDAQ: ITRI), which is innovating new ways for utilities and cities to manage energy and water, today announced a new brand identity reflecting the company’s evolution and a new era of delivering enhanced intelligence to create a more resourceful world. The new brand identity reflects Itron’s commitment to creating new efficiencies, connecting communities, encouraging sustainability and increasing resourcefulness.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240214395189/en/
“Itron stands at the forefront of a rapidly changing world where the challenges of energy and water scarcity, escalating demand and enabling the energy transition are more pressing than ever,” said Tom Deitrich, Itron’s president and CEO. “Our new brand identity honors our history and reflects the company we have become while demonstrating our industry leadership and dedication to understanding and solving our customers' evolving needs.”
As a proven leader of the Industrial Internet of Things (IIoT) with one of the largest connected platforms and installed bases in the energy, water and smart city sectors, Itron is providing more intelligence at the grid edge and driving a smoother transition to cleaner energy and water delivery while transforming the way grid operators address critical challenges. Itron invents new ways for cities and utilities to work together so they can cost-effectively leverage the same intelligent grid edge infrastructure to deliver multiple services and applications on a reliable, resilient network capable of serving all stakeholders.
This new brand identity serves as a strategic move for Itron as the company expands its offerings, signaling to the market the company’s evolution and growth in several key focus areas:
- Electricity: Enabling improved visibility and control at the grid edge. Boosting utility and city customers’ energy efficiency and cost savings and enabling the transition to lower-carbon energy, EVs and a more robust, resilient and reliable grid.
- Water: Safeguarding the water supply, finding leaks, reducing waste and improving safety.
- Smart Cities: Connecting, protecting and unlocking endless possibilities for more sustainable, thriving communities.
- Gas: Ensuring safety and integrity in the natural gas delivery system while unlocking more insights from that same system than ever before.
- Sustainability: Leaving a legacy of responsible energy and water management and reducing both Itron’s and its customers’ carbon footprint.
As part of the refreshed brand identity, Itron is introducing a more modern logo that showcases a leaner font, a more upright design, more modern lines and richer, deeper colors. The ray or beam of light shining out from the ‘O’ symbolizes Itron’s leadership and ability to light the way forward for the industry.
“At Itron, we are a catalyst for positive change, delivering intelligent, secure and reliable solutions that power homes, ensure the delivery of clean water and contribute to well-lit and safer streets, enabling a brighter, more sustainable future,” said Marina Donovan, Itron’s vice president of global marketing, ESG and public affairs. “Our new brand identity reflects and projects our edge intelligence offerings and a new era for Itron.”
For more details on Itron’s new brand identity, see the Itron Press Kit, which features brand guidelines, logo files and updated fact sheet and watch the brand history video. Also visit Itron at DISTRIBUTECH International, Feb. 27-29, 2024, in booth #2200 where the new brand will be on full display.
About Itron
Itron is a proven global leader in energy, water, smart city, IIoT and intelligent infrastructure services. For utilities, cities and society, we build innovative systems, create new efficiencies, connect communities, encourage conservation and increase resourcefulness. By safeguarding our invaluable natural resources today and tomorrow, we improve the quality of life for people around the world. Join us: www.itron.com.
Itron® is a registered trademark of Itron, Inc. All third-party trademarks are property of their respective owners and any usage herein does not suggest or imply any relationship between Itron and the third party unless expressly stated.
Additional Resources
- LinkedIn: https://www.linkedin.com/company/itroninc/
- X: https://twitter.com/ItronInc
- Newsroom: www.itron.com/company/newsroom
- Blog: https://blogs.itron.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240214395189/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom